

Adalimumab/infliximab

S

Lower serologic response: 6 case reports

In a prospective, observational, multicenter study conducted between 29 December 2020 and 5 May 2021 at IBD centers located in Israel, involving 258 patients, six patients (4 men and 2 women) were described who developed lower serologic response to vaccination with tozinameran following treatment with adalimumab (n=1) and infliximab (n=5) for inflammatory bowel disease (IBD) [*dosages and routes not stated*].

The patients, who had IBD were receiving treatment with infliximab (n=3), infliximab and unspecified immunomodulatory therapy (n=1), infliximab and unspecified 5-aminosalicylic acid (n=1), and adalimumab with unspecified steroids (n=1) for IBD. The patients received the first vaccine dose with tozinameran [covid-19 vaccine BNT162b2; Pfizer/BioNTech] for COVID-19. However, despite vaccination, the patients remained seronegative. The significantly lower antibody levels were attributed to the anti-TNF α treatment. Thereafter, the patients received the second dose of Pfizer-BioNTech-vaccine and were seropositive.

Edelman-Klapper H, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNF α . *Gastroenterology* 162: 454-467, No. 2, Feb 2022. Available from: URL: <http://doi.org/10.1053/j.gastro.2021.10.029>

803653806